ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma disease medicine

Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019 | 2 min read
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Alzheimer Research Joins the Mainstream
Christine Bahls | Jan 20, 2002 | 5 min read
In 1977, Alzheimer Disease researcher Peter Davies spoke with some neurologists about his work, which he began a year earlier. "One [neurologist] said, 'This is lovely..., but why don't you work on something that is more common?'" he remembers. Davies says the comment epitomized scientists' then-dismissive attitude about Alzheimer Disease (AD). When Alois Alzheimer first identified this memory-destroying disorder in 1907, his patient was a 50-year-old woman; a very early age, as researchers now
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced
African Sleeping Sickness: A Recurring Epidemic
Ricki Lewis | May 12, 2002 | 5 min read
African trypanosomiasis is making an unwelcome comeback. But unlike other returning diseases, this one has a drug treatment—eflornithine—that disappeared from the market when it failed to cure cancer. Yet like Viagra's origin from a curious side effect in a clinical trial, so too was eflornithine reborn. "When it was discovered that it removes mustaches in women, it suddenly had a market: western women with mustaches," says Morten Rostrup, president of the international council for M
Outwitting the Perfect Pathogen
Megan Scudellari | Jan 1, 2014 | 8 min read
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

Run a Search

ADVERTISEMENT